Can the pathology of a thyroid nodule be determined by positron emission tomography uptake?

Otolaryngology - Head and Neck Surgery (United States)

Volumn 146, Issue 6, 2012, Pages 906-912

  Boeckmann, Jacob ^a   Bartel, Twyla ^a,b   Siegel, Eric ^b   Bodenner, Donald ^a,c   Stack, Brendan C ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

benign; cytology; FDG PET CT; malignant; pathology; prediction; thyroid nodule

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGE; AGED; ASPIRATION BIOPSY; BENIGN TUMOR; CYTOLOGY; DRUG UPTAKE; ECHOGRAPHY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID NODULE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; ROC CURVE; THYROID NODULE; YOUNG ADULT;

EID: 84864747023     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599811435770     Document Type: Review

References (29)

1. Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med. 2004 ; 351: 1764-1771
2. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993 ; 328: 553-559
3. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 ; 19: 1167-1214
4. Haber RS, Weiser KR, Pritsker A, Reder I, Burstein DE. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid. 1997 ; 7: 363-367
5. Diehl MR, Jörn H, Brandt-Mainz K, et al. Fluorine-18, uorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study. Eur J Nucl Med. 2001 ; 28: 1671-1676
6. Miller ME, Chen Q, Elashoff D, Abemayor E, St John M. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review. Head Neck. 2010 ; 33: 562-565
7. Choi MY, Chung JK, Lee HY, et al. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med. 2006 ; 20: 547-552
8. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma on [18F] FDG-positron emission tomography scanning. J Clin Endocrinol Met. 2006 ; 91: 498-505
9. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of 18F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative 131I scanning results after therapy. J Nucl Med. 2001 ; 42: 1464-1469
10. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope. 2005 ; 115: 237-243
11. Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope. 2005 ; 115: 1074-1078
12. Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med. 2006 ; 47: 609-615
13. Bae JS, Chae BJ, Park WC, et al. Incidental thyroid lesions detected by FDG-PET/CT: prevalence and risk of thyroid cancer. World J Surg Oncol. 2009 ; 7: 63
14. Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentaloma identified by 18F-fluorodeoxyglucose-positron emission tomography. Surgery. 2001 ; 130: 941-946
15. Chen YK, Ding HJ, Chen KT, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res. 2005 ; 25: 1421-1426
16. King DL, Stack BC, Spring PM, Walker R, Bodenner DL. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. Otolaryngol Head Neck Surg. 2007 ; 137: 400-404
17. Kang BJ, Hyun J, Baik JH, Jung SL, Park YH, Chung SK. Incidental thyroid uptake on F-18 FDG PET/CT: correlation with ultrasound and pathology. Ann Nucl Med. 2009 ; 23: 729-737
18. Mitchel JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S. Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. Surgery. 2005 ; 138: 1166-1175
19. Yasuda S, Shohtsu A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology. 1998 ; 207: 775-778
20. Boerner AR, Voth E, Theissen P, Wienhard K, Wagner R, Schicha H. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro- deoxyglucose positron emission tomography. Thyroid. 1998 ; 8: 765-772
21. Karantanis D, Bogsrud TV, Wiseman GA, et al. Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland. J Nuclear Med. 2007 ; 48: 896-901
22. Jeong HS, Baek CH, Son YI, et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol. 2006 ; 65: 402-407
23. Rheingold SR, Neugut AI, Meadows AT Cancer Medicine. Bast RC Kufe DW Pollock RE, ed. Hamilton, Canada: BC Decker ; 2623-2631.
24. Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab. 2003 ; 88: 410-414
25. Eloy JA, Brett EM, Fatterpekar GM, et al. The significance and management of incidental [18F]fluorodeoxyglucose-positron-emission tomography uptake in the thyroid gland in patients with cancer. Am J Neuroradiol. 2009 ; 30: 1431-1434
26. Kresnik E, Gallowitsch HJ, Mikosch P, et al. Fluorine-18- fluorodoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery. 2003 ; 133: 294-299
27. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009 ; 34: 576-584
28. Huang , Zhou T, Ma L. Standard uptake value and metabolic tumor volume of (18)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011 ; 38: 1628-1635
29. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009 ; 27: 535-541